Transarterial chemoembolization with rivoceranib and camrelizumab for BCLC stage C hepatocellular carcinoma.

ABSTRACT:

Background

Transarterial chemoembolization (TACE) and systemic therapy are frequently applied for advanced hepatocellular carcinoma (HCC), but their combined therapeutic potential remains uncertain. Here, the clinical efficacy and safety of TACE together with rivoceranib plus camrelizumab in Barcelona Clinic Liver Cancer (BCLC) stage C HCC were investigated.

Methods

Between January 2021 and December 2024, 167 consecutive cases of BCLC stage C HCC were retrospectively analyzed. Eighty-three received rivoceranib-camrelizumab with TACE, and 84 received rivoceranib-camrelizumab alone. Comparisons of baseline characteristics, tumor response, long-term outcomes, and adverse events were conducted.

Results

Baseline variables were balanced between groups. Combination therapy a

SUBMITTER: Zhu R 

PROVIDER: S-EPMC12727550 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature